Clinical trial

Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer

NCT07490210

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

RADIATION · Unmapped registry intervention Metastasis-directed radiotherapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Rezvilutamide + ADT Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Radical prostatectomy Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-05-01

PhasePHASE2

Conditions

Oligometastatic Prostate Cancerunresolved

Interventions

Metastasis-directed radiotherapyRADIATION

Rezvilutamide + ADTDRUG

Radical prostatectomyPROCEDURE

Sponsors & collaborators

Fudan Universitylead sponsor

Jiangsu Hengrui Pharmaceutical Co., Ltd.collaborator

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07490210 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.